Theravance Biopharma (TBPH) Stock Statistics & Valuation Metrics

Theravance Biopharma has a market cap or net worth of $838.25M. The enterprise value is $638.40M.

Theravance Biopharma has 51,553,005 shares outstanding. The number of shares has decreased by -2.65% in one year.

Theravance Biopharma’s return on equity (ROE) is 0.36 and return on invested capital (ROIC) is -2.37%.

The current PE Ratio of Theravance Biopharma is ―. Theravance Biopharma’s PEG ratio is -0.03.

In the last 12 months, Theravance Biopharma had revenue of 107.46M and earned 105.89M in profits. Earnings per share was 2.10.

In the last 12 months, operating cash flow was 268.78M and capital expenditures -42.00K, giving a free cash flow of 268.74M billion.

Theravance Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Theravance Biopharma upcoming earnings date is Aug 5, 2026, Before Open (Confirmed).

Theravance Biopharma as a current ratio of 10.93, with Debt / Equity ratio of 25.22%

In the past 12 months, Theravance Biopharma has paid 23.35M in taxes.

Theravance Biopharma EV to EBITDA ratio is -109.83, with an EV/FCF ratio of 3.56.

Theravance Biopharma has $394.67M in cash and marketable securities with $73.30M in debt, giving a net cash position of $321.37M billion.

Gross margin is 80.37%, with operating margin of -12.33%, and net profit margin of 98.54%.

The average price target for Theravance Biopharma is $16.61, which is 11.43% higher than the current price. The consensus rating is Moderate Buy